Introduction
The ability to drive a motor vehicle is considered fundamental in daily living and employment in the modern era. However, this privilege is dependent on the safety of the individual behind the wheel.
The most important aspect of declaring an individual medically fit to drive is the risk of incapacity while driving, with its inherent risk of resulting in a road traffic accident that may not only involve the individual concerned, but also other drivers. Doctors are often required to pass judgement on the safety of an individual to drive once they have been diagnosed with an arrhythmia or are receiving treatment for it. This decision can have far-reaching consequences for the individual including their livelihood.
In the UK, European countries, and the USA, guidelines have been issued by various authorities detailing the criteria for declaring an individual with an arrhythmia safe to drive. 1 -4 Within these guidelines a distinction is made between those individuals driving passenger cars from those who drive heavy goods and public transport vehicles, for whom more stringent criteria are used to declare medical fitness to drive. More stringent criteria are used for such licence holders as they drive larger vehicles with momentum at the time of an accident and hence impact likely to be higher and consequences more significant. Such drivers are more likely to spend longer periods of time driving thereby increasing the risk of arrhythmia occurring during driving. Knowledge of the risks of arrhythmia occurrence while driving as well as the physiological basis for arrhythmia triggered by driving will allow physicians to make informed decisions with the existing guidelines regarding this issue. This review article explores the propensity of developing arrhythmias while driving as well as the physiological basis of developing arrhythmia while driving. We will also review the current driving guidelines in the USA, UK, and Europe.
Impact of arrhythmia on driving
Motor vehicle accidents secondary to incapacity caused by arrhythmias are infrequent. Grattan and Jeffcoate 5 showed that 1.5 per thousand non-fatal accidents and 4 per thousand fatal accidents were attributable to driver incapacity caused by medical illness. The same study showed that the commonest medical cause for incapacity resulting in accidents was epilepsy, with heart conditions accounting for only 8%. Most cases of road traffic accidents are related to human error. A retrospective analysis of patients investigated for impaired consciousness while driving showed that the commonest diagnosis made was vasovagal syncope, found in 30% of the 71 patients studied. 6 With regard to arrhythmias in such patients, the commonest arrhythmia diagnosed in this population was supraventricular tachycardia (25%, diagnosed with electrophysiology studies). Ventricular tachycardia (VT) was confirmed in 17% of patients, with half of these found by the interrogation of previously implanted cardioverter-defibrillator (ICD). An advanced atrioventricular block was found in 10% of the study population. Treatment of these conditions resulted in an absence of further episodes of the loss of consciousness while driving during the mean follow-up period of 5.4 years in all but one patient, where a secondary diagnosis of vasovagal syncope was found and treated accordingly. This study does not establish a causal relationship between the presence of these arrhythmias and the presenting incident, but merely suggests that these conditions were found in the study population. It should also be noted that in 20% of the study population, no diagnosis was found. Life-threatening arrhythmias, such as VT or ventricular fibrillation (VF), are thought to pose the greatest risk of driver incapacity with consequent road traffic accident. In a study performed in the USA, surveys were sent to 742 physicians following up patients with ICDs for secondary prevention. Data from 452 responses over a 12-year period showed that 30 patients suffered an accident attributed to the discharge of their ICDs. 7 Of these, nine were fatal involving the driver or passenger in the car. However, the estimated fatality rate was shown to be significantly lower than the general population (7.5/100 000 patient-years for ICD drivers vs. 18.4/100 000 patient-years for the general population, P , 0.05).
The estimated injury rate from the same study for ICD-implanted drivers was also shown to be significantly less than the general population (17.6/100 000 patient-years for ICD drivers vs. 2224/ 100 000 patient-years for the general population, P , 0.05). In addition, of the surveys returned, only 10% of all defibrillator discharges during driving resulted in accidents. It should be noted that this study involved patients with ICD implanted between 1980 and 1992. In comparison with modern ICDs, previous models were often slower at detecting and discharging shocks 8 -they had slower charging times, non-intracardiac electrogram-based arrhythmia recognition and also did not have anti-tachycardia pacing algorithms that may pace-terminate VT and hence obviate the need for shock discharge. Persistence of VT due to slower detection and charging may result in deterioration into VF or haemodynamic instability associated with VT. Hence, there would be a greater chance of syncope caused by a malignant arrhythmia during this time period than in modern day driving population with ICDs.
With the advent of anti-tachycardic pacing, it has been demonstrated that some VT episodes can be terminated with overdrive pacing. The Painfree RXII trial demonstrated that anti-tachycardia pacing (ATP) is effective at termination of VT, often without the patient being aware of the occurrence of the VT episode 9 . Similarly, a review of patients who had ICD implanted for secondary prevention indications revealed that in a follow-up of 241 patients over a 36-month period after implant, 5% of patients suffered an ICD shock while driving but these patients did not report syncope during these shocks. Out of the 11 accidents that occurred during this time, only 1 was caused by the driver and again was not attributed to ICD shock or syncope. There were no fatal accidents. 10 Kou et al. 11 showed that out of 180 patients with ICDs, 16 lost consciousness. More importantly, this study also showed that the absence of syncope during one episode of ICD shock delivery did not reliably predict a similar occurrence with subsequent ICD shocks. A separate retrospective study by Bansch et al. 12 showed that the incidence of syncope following ICD shock declined with time from implantation. This study also showed that an impaired left ventricular function and the induction of VT or atrial fibrillation (AF) during electrophysiological testing were associated with a higher incidence of syncope in such patients. These risk factors help to identify those individuals at highest risk of syncope during driving, an aspect which is reflected by driving recommendations. 1 -3 Larsen et al. 34 found that the incidence of recurrent ICD shocks decreases and levels off at 6-month post-implantation, informing the decision of driving restriction for 6-month post-ICD implantation.
There have been no trials that have specifically looked at incidences of ICD discharges while driving in patients receiving ICD for primary prevention. However, extrapolation of data from three major primary prevention ICD trials and comparing this with projected time spent in a vehicle estimates that the likelihood of an event while driving (either from arrhythmia or incapacitation by shock or anti-tachycardic pacing) is ,1%. 4 Highest risk of ICD discharge in this group is still perceived to be immediately after device implantation, especially for inappropriate shocks, although data to support this are lacking. While ATP may prevent incapacity caused by shock therapy in some cases, it has been shown that fast burst pacing can be associated with cerebral dysfunction and impaired psychomotor performance. 13 In addition, ATP may accelerate haemodynamically stable VT into VF, and hence result in incapacity prior to delivery of shock. A prospective study of 770 patients receiving ICD implantation for primary or secondary prevention revealed that in patients receiving ATP for termination of fast VT, syncope occurred in 0.2% and pre-syncope occurred in 0.4% of cases; in the remainder ATP and termination of fast VT was asymptomatic. 14 In the PITAGORA ICD trial, the incidence of fast VT-related syncope following burst or ramp ATP was 0.97%, 15 a figure which was comparable with the rates seen in the Painfree Rx study 16 . These studies illustrate that while patients with ICDs can have accidents caused by arrhythmias or discharge of their device, this is a relatively infrequent event and the relative safety of driving with such devices could be supported. The highest risk of arrhythmia, appropriate or inappropriate ICD discharge is within the first 6 months of implantation. Also, patients at a higher risk of recurrence of ventricular arrhythmias post-ICD insertion may be identified, these risk factors are reflected in the UK and European guidelines for medical fitness for driving (see section below).
There has been evidence that incapacitation can occur in relatively more benign arrhythmias during driving. A review of 256 drivers with supraventricular tachycardia awaiting radiofrequency ablation revealed that 57% of patients experienced symptoms from SVT during driving. Forty-two per cent of these patients felt they had to stop driving because of their symptoms, which included near-syncope and syncope in over half of these patients. 17 In addition, arrhythmias such as AF have an inherent risk of thrombo-embolic events, which if occurring while driving, may Driving and arrhythmia also lead to driver incapacity. Control of symptoms caused by arrhythmias is the key to allowing an individual to recommence driving safely.
Physiological basis of arrhythmia during driving
Postulated mechanisms that may lead to an increased frequency of arrhythmias during driving are two-fold. First, it has been demonstrated that driving can trigger psychological stress in the form of anger and anxiety. In turn this can lead to elevated levels of catecholamines resulting in perturbations of the autonomic nervous system and stimulation of the sympathetic nervous system leading to an increased propensity to arrhythmias. Elevated levels of urinary catecholamines and cortisol have been demonstrated in long-distance coach drivers during periods of driving compared with measurements taken on days off work. 18 In a study by Taggart et al. examining the effects of driving on the normal and abnormal heart, driving was associated with an increased heart rate and precipitation of angina in patients with known coronary disease. 19 Although following a city drive, there was no significant increase in catecholamine levels, this was only measured in three patients and at the end of the drive. Elevated noradrenaline levels were seen in racing car drivers. Salivary amylase levels have been shown to be increased during sympathetic activation and can act as an index of plasma noradrenaline concentrations during stressful situations; one which can be measured non-intrusively and by causing minimal stress by obtaining samples. Salivary amylase levels have been shown to increase significantly during a simulated driving excercise. 20 Such simulated driving exercises have also demonstrated physiological cardiovascular changes (elevated heart rate, blood pressure, and total peripheral resistance) associated with anger precipitated by traffic jams during the simulated journey. 21 These features also are reflective of enhanced sympathetic activity.
There have been a number of physiological studies that have showed increased tendency to develop arrhythmias with anger. In one such study, patients with ICDs were asked to keep a diary of emotional states recorded up to 2 h before a spontaneously delivered ICD shock, and also during a control week. 22 This study showed that in 107 confirmed episodes of ventricular arrhythmia requiring shock, there was a significantly greater proportion of patients reporting anger in the 15 min prior to shock discharge compared with control [anger recorded in 15% of shock events compared with 3% of control periods, odds ratio (OR) ¼ 1.83, P ¼ 0.04]. This indicates that the presence of anger may have resulted in an increased frequency of ICD shocks secondary to ventricular arrhythmias. Although in the same study, physical activity was also higher prior to shock delivery, adjustment for this still confirmed that anger was significantly associated with ICD shock therapy for ventricular arrhythmia.
A separate study showed that when patients with ICDs were exposed to mental stress in the form of anger recall or mental arithmetic, the induction of VT using non-invasive programmed stimulation (NIPS) resulted in shorter cycle lengths and increased number of patients requiring DC shock to terminate VT, compared with similar patients who underwent NIPS under sedation. 23 The same study also demonstrated that in the more aroused state, mean nor-epinephrine levels measured at the time of NIPS were higher than in sedated patients. In those patients with elevated catecholamines, there was earlier induction and faster VT induced at NIPS. Additionally, in patients where mean rise in the plasma norepinephrine level was .50%, the VT was harder to terminate with all such patients requiring shock to terminate VT, compared with patients in whom the plasma norepinephrine level rise was ,50%, in whom pace-termination was sufficient. From these studies, it would appear that stressful activities such as driving have a destabilizing effect on ventricular arrhythmias, resulting in an increased frequency of arrhythmias as well as the generation of malignant arrhythmias that are harder to terminate.
Another physiological mechanism by which driving may lead to arrhythmias is exposure to air pollution. Several epidemiological studies have shown a correlation between increases in short-term ambient air pollution and ventricular arrhythmias. 24 Episodes of paroxysmal AF have also been associated with immediate increases in ozone concentrations. This study also showed a non-significant positive correlation between NO 2 , particulate matter levels, and episodes of fast paroxysmal AF. These correlations were only present for short-time periods, suggesting that there is an immediate effect of these pollutants on precipitating AF. 25 More recently, a case-crossover study of 211 patients with ICDs performed in Gothenberg and Stockholm looked at exposure to PM10 and NO 2 and the incidence of ventricular arrhythmias. 26 They
showed an association between 2 h moving averages of PM10 and ventricular arrhythmia compared with a control period (OR ¼ 1.31, 95% CI: 1.00-1.72). This suggests that particulate matter exposure may have an immediate effect on an increasing risk of ventricular arrhythmia. This study also showed that proximity to regions of ambient air pollution was directly correlated with an increased rate of ventricular arrhythmias. The mechanism by which particulate matter leads to the development of arrhythmia is likely to be related to its effect on cardiac autonomic tone, a viewpoint that is supported by effects of shortterm air pollution on heart rate variability. 27, 28 Particulate matter and air pollution may also result in increased myocardial ischaemia and risk of myocardial infarction. Particulate matter from air pollution and exhaust fumes can directly affect platelet activity, endothelial function, and haemostasis leading to an increased risk of arterial and venous thrombotic events. 29 In a double-blind, randomized crossover study, 20 men with prior myocardial infarction were exposed in separate occasions to dilute diesel exhaust or filtered air for a total of 1 h both at rest and on moderate exercise. Exercise stress testing in these men demonstrated significantly an increased ischaemic burden following exposure to diesel exhaust compared with filtered air. 30 The investigators of this study also demonstrated reduction in tissue plasminogen activator release 6 h following exposure to diesel exhaust fumes, suggesting reduced endogenous fibrinolytic activity that may predispose to an increased risk of myocardial infarction in patients with preexisting coronary disease. Indeed, a study involving 607 patients who had suffered an acute myocardial infarct demonstrated a two-to three-fold increased risk of MI occurring within 1 h of exposure to traffic compared with no exposure to traffic (OR ¼ 2.73, 95% CI: 2.06-3.61). This finding was following adjustment in the study cohort for severe exertion, being outside and for getting up in the morning. 31 Higher levels of PM10 and NO 2 have also been associated with an increased risk of myocardial infarction 1-6 h after exposure from the MINAP data set, 32 although there was not shown to be a sustained increased risk beyond 6 h following exposure to particulate matter.
Arrhythmia precipitated by driving: evidence base
Although there may be a physiological basis to the precipitation of arrhythmia during driving, there have been very few studies that have directly examined the ability of driving to trigger an arrhythmia. This has now become more feasible with the advent of ICDs, which allow for the interrogation of devices to examine periods during driving and periods of rest to ascertain whether there is a causal relationship between driving and arrhythmia. The triggers of ventricular arrhythmia (TOVA) study is a multicentre case-crossover study that compared the risk of the occurrence of VT/VF during and up to 60 min after driving with that during other activities. 35 Patients were asked to record driving activity prior to shock delivery. This was compared with control periods, where no driving occurred. In total, 193 shocks with data on exposure to driving prior to shock delivery were collected from a population of 1188 patients enrolled in the study. One possible reason why there may be a delayed effect in arrhythmia generation is that driving may have an 'inductive effect' to lower the threshold for arrhythmia precipitation. Subsequent activity during this primed phase immediately after driving may lead to the arrhythmia. Alternatively, an increased incidence of arrhythmia post-driving may be related to the exposure of particulate matter after getting out of the car, with enhanced sympathetic tone during driving acting as the priming agent. However, it must be borne in mind that this study is dependent upon accurate reporting of incidences of shock delivery during driving. Fear of the repercussions from such reporting may have led to individuals failing to report such cases. In addition, although this study does suggest an association, it cannot prove causality as confounding variables were not accounted for, such as additional activities performed during or after driving. Also, patients recruited in this study were all patients who have had ICD implantation for secondary prevention measures, arguably a population at greater propensity to developing malignant arrhythmias than the general population. Nevertheless, it does lend support to the notion that the activity of driving may precipitate an arrhythmia, albeit a low risk. This study showed that the incidence of shock delivery amounted to one episode per 25 116 person-hours spent driving. In comparison, the absolute risk of experiencing a shock delivered for VT or VF was one shock per 56 260 personhours spent in all activity (not only driving). This suggests that one might be two-fold more likely to gain an ICD shock during driving than overall in the study, albeit that the overall risk of developing a shock is low. Looking at the incidences, where shock was delivered during driving, of the seven cases in this study only one resulted in a motor vehicle accident. Again, the possibility of reporting bias must be taken into account when considering this figure.
The AVID trial showed that a similar proportion of patients, in this case 8% of drivers, experienced ICD shocks while driving. 36 None of these shocks resulted in an accident. Of the 559 patients who resumed driving after ICD implantation in this trial, 2% reported syncope while driving, 11% had dizziness or palpitations requiring the driver to stop the vehicle, and 22% had dizziness or palpitations, but were still able to drive. The annual accident risk in this population was less than the general population (3.4 vs. 7.1% among US citizens), and among the trial participants, the apparent arrhythmia-related accident rate was 0.4%.
Guidelines for medical fitness to drive
As shown above, although there is some evidence to support a pathophysiological basis for an increased frequency of arrhythmias during driving, there is a lack of convincing causal evidence linking the activity of driving with the generation of arrhythmia. In addition, there also appears to be lower rates of motor vehicle accidents among patients with ICD and arrhythmias compared with the general population, although sample sizes and underreporting by study participants may play a role. Nevertheless, the key issue here is that patients with a history of arrhythmias have a pre-diagnosed condition that predisposes that individual to syncope at the driving wheel. From a physician's perspective, this raises the dilemma that the patient has a condition that, if allowed to drive, may cause harm to themselves and others on the road. Hence, guidelines have been devised to assist physicians in deciding whether a patient with an arrhythmic condition is safe to drive 1 -4 . The guidelines for USA, UK, and European countries are summarized in Driving and arrhythmia
Arrhythmias
With regard to narrow complex tachycardias (AF, atrial flutter, atrial tachycardia, AVNRT/AVRT), all three guidelines recommend driving should cease while patients are symptomatic. It is noteworthy that in a retrospective analysis of patients who suffered impaired consciousness while driving, the commonest diagnosed arrhythmia was supraventricular tachycardia. 6 For Class 1 drivers, both UK and USA guidelines recommend driving may resume once symptoms are controlled for 1 month. For Class 2 drivers, the DVLA recommends arrhythmia control for 3 months, while the USA stipulate only 1 month as with Class 1 drivers. In the ESC guidelines, 3 a resumption of driving is permitted once the arrhythmia is controlled. Additional requirements from the ESC recommendations for Class 2 licence holders include the LVEF should be .40% (this is also recommended in the UK guidelines), and may reflect the fact that arrhythmias are more likely to cause haemodynamic compromise in patients with severe LV systolic dysfunction. For Broad Complex tachycardias (non-sustained VT, VT, and VF), driving is disqualified if the arrhythmia causes incapacity. Driving can resume if the arrhythmia is controlled for 4 weeks in the UK DVLA guidelines for Class 1 drivers. In the USA guidelines, for Class 1 drivers a distinction is made between NSVT, VT, and VF; for NSVT driving must cease if this causes symptoms and may resume if the NSVT is controlled on therapy for 3 months, for VT there is a 6-month restriction post-therapy-however, if this is idiopathic VT with no evidence of underlying structural disease, this restriction is reduced to 3 months arrhythmia-free on therapy. Recommendations are also given for Class 2 licence holders, however, such patients may also receive ICD therapy, for which there are separate recommendations (see below).
For symptoms or incapacity caused by bradyarrhythmias, all three sets of guidelines are clearly in agreement that driving must discontinue until appropriate treatment, including pacemaker therapy, is instituted. All guidelines recommend driving cessation for 1 week following pacemaker implantation for Class 1 drivers. For Class 2 drivers, the UK guidelines recommend 6-week cessation, the USA guidelines recommend 4-week cessation, while the ESC guidelines recommend driving can recommence if there are no persisting symptoms.
Following implantable cardioverter-defibrillator implant and implantable cardioverter-defibrillator therapy
The advent of ICDs has changed the way in which malignant arrhythmias are viewed in this respect. However, the guidelines address not only the fact that the underlying arrhythmia still exists, but also the consequences of ICD discharge while driving. In all three guidelines, the presence of an ICD permanently restricts a patient from holding a Class 2 driving licence. Since major trials such as MADIT II 40 and SCD-HeFT 41 demonstrated the benefit of ICD implantation for primary prevention, the rate of ICD implantation has increased and this has been recognized in the guidelines, with an update for Class 1 drivers recently added to the USA recommendations in 2007 to address this issue. 4 Similarly, the European guidelines were updated in 2009 with regard to driving restrictions in patients with ICDs. 33 The USA, UK, and European guidelines all cover driving restriction following an ICD shock. 1, 3, 4, 33 The restrictions on driving in the context of ICD are comparable between the three groups of guidelines. It is notable, however, that following ICD implantation for secondary prevention, the 2009 EHRA guidelines only impose a 3-month restriction. 33 The reduced restriction imposed by the EHRA guideline statement of 2009 is based on the results of the TOVA study 35 which suggests that not only the risk for ICD shock for VT/VF was not elevated during driving (RR: 1.05, 95% CI: 0.48-2.30), but also that the absolute risk was low (within 1 h of driving, this is estimated as being 1 shock per 25 116 person-hours spent driving). The 3-month figure was given as a consensus opinion of time taken to recover from a cardiac arrest, and comes with the proviso that functional class and cognitive functions need to be assessed before a resumption of driving can be permitted. In comparison, the American Heart Association guidelines refer to the study by Larsen et al., 34 which demonstrated that the highest risk of an ICD discharge post-implantation is within the first month, after which the risk is moderately elevated between months 2 and 7, and then this declines substantially. Hence, the 6-month cut-off is used post-implantation and shock therapy, which is also the guidance from the UK DVLA. However, there is a noticeable difference in the UK guidelines that if ICDs are implanted for secondary prevention where ventricular arrhythmia did not cause incapacity, driving can resume 1 month after ICD implantation providing all the following are met: (i) LVEF .35%, (ii) no fast VT (cycle length ,250 ms) is induced on electrophysiological study, and (iii) any induced VT could be pace-terminated by the ICD twice, without acceleration, during the post implantation study. The USA and EHRA recommendations do not make any distinction between ICD implant for secondary prevention with or without incapacity during the ventricular arrhythmia. With regard to ICD implantation for primary prevention, the EHRA recommendations are based on data suggesting that overall likelihood of an ICD discharge in primary prevention patients while driving is estimated at ,0.15%. 33 Hence, the recommendation for 4 weeks' restriction is to cover the time period during which lead dislodgements, perforations, and pocket-related problems are likely to occur. The USA guidelines also suggest that in patients receiving primary prevention ICD implantation, restriction post-implant is not related to likelihood of ICD discharge, and only a 1-week period is required which is for recovery from the operation. Within the UK DVLA guidelines, there is a 1-month restriction, indicating relative agreement in all three guidelines that the risk of shock following ICD implantation for primary prevention is low. Following ICD therapies, all of the guidelines require correction of the cause of either appropriate or inappropriate ICD therapy prior to a resumption of driving. Both the USA and UK guidelines recommend 6 months' restriction from driving following an appropriate ICD shock, with corrective measures to prevent recurrence of VT or VF (either pharmacologically or by ablation). The recommendations from the August 2011 UK DVLA guidelines are summarized in Figure 1 . In contrast, EHRA recommends that only a 3-month restriction is required. The difference in these timeframes is accounted for by the interpretation of data from Freedberg et al., 37 suggesting that the mean time to recurrent ICD therapy was 66 + 93 days for patients who received implant for secondary prevention. There is little published data for recurrent arrhythmias following shocks in ICDs implanted for primary prevention; however, the EHRA guidelines do cite data from MADIT II 40 and SCD-HeFT 41 that suggest patients with ICDs for primary prevention are at an increased risk of recurrent arrhythmias if appropriate ICD therapy occurs. A recent study conducted in 2786 patients with ICD implanted for primary and secondary prevention has shed further light on the incidence of recurrent shocks and their impact on subsequent driving restriction. 38 The annual risk of harm (RH) associated with an appropriate or inappropriate shock was calculated as a product of proportion of time spent on driving, type of vehicle, yearly risk of sudden cardiac incapacitation and probability that the event would result in a fatal or injury producing accident, based on a formula developed by the Canadian Cardiovascular Society Consensus Conference. 39 It was found that, RH falls below the designated acceptable level of 5 per 100 000 ICD patients at 4 months following an appropriate shock in primary prevention patients, and at 2 months following an appropriate shock in secondary prevention patients. Following an inappropriate shock in both primary and secondary prevention patients, this remains below the acceptable cut-off valve immediately post-shock. This is slightly counter-intuitive in that it suggests a shorter 'ban' is required for secondary as opposed to primary prevention patients following an appropriate shock. This result was driven by the finding in this study cohort that a second appropriate shock comes soon after a first shock in primary prevention patients. However, this has to be interpreted in the light of the study limitations in that it was an observational study in a single centre with a longer follow-up period in secondary than primary prevention patients and anti-tachycardia pacing data was discarded from the analysis. Nonetheless, for inappropriate shocks, the findings from this study lend weight to no required restriction in Class 1 licence holders post-shock which is in agreement with the current guidelines.
Conclusion
Although there is a low frequency of arrhythmia occurring while driving, driver incapacity caused by such arrhythmias may result in a fatal accident involving not only the patient, but also other road users. There is evidence supporting a pathophysiological basis for driving as a trigger of arrhythmia. This has been supported by recent studies that have shown a possible causal relationship between driving and ventricular arrhythmia. These aspects should allow physicians to be able to apply guidelines to individuals with arrhythmias in determining their safety to drive. While there are some differences between international guidelines, there appears to be a general consensus that most arrhythmia conditions require correction followed by a period of observation during which driving is restricted in the presence of arrhythmias causing incapacity. ICD therapy has changed the way in which patients with malignant arrhythmias are managed with an important prognostic benefit. Special attention is paid to such individuals with regard to driving restrictions, and advances in ICD therapy including anti-tachycardia pacing and the evidence supporting safety while driving with these implanted devices have been reflected by a reduction in the restriction in the recent EHRA recommendations. It should be remembered, however, that patients with cardiovascular disease may have other conditions that will also affect an individual's ability to drive and the relevant guidelines must be applied. For instance, arrhythmias occurring following an MI will also be subject to restrictions imposed by MI rather than the arrhythmia per se.
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